Novartis CEO joins Anthropic Board of Directors, with the Independent Trust's appointed directors taking the majority seat for the first time

ME News Report, April 14 (UTC+8), according to 1M AI News monitoring, Anthropic announced that Novartis CEO Vas Narasimhan, a global pharmaceutical giant, has joined its board of directors, appointed by the company’s Long-Term Benefit Trust. Following this appointment, the trust-appointed directors now hold the majority seats on the seven-member board. Anthropic’s Long-Term Benefit Trust is an independent organization; its members have no financial interests in Anthropic, and their responsibility is to ensure that corporate governance balances commercial success with public welfare missions. Currently, the board has seven members: Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, Chris Liddell, and Narasimhan. Narasimhan is a medical scientist who led the research and approval of over 35 new drugs during his tenure as Novartis CEO. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis projects in India, Africa, and South America, and is now a fellow of the National Academy of Medicine. Daniela Amodei, co-founder and president of Anthropic, stated that Narasimhan’s experience in one of the most heavily regulated industries in the world will help bring powerful new technologies to market safely and at scale, which is exactly what Anthropic does every day. (Source: BlockBeats)